March 9 – 11, 2011
The New York Academy of Sciences
Presented by the New York Academy of Sciences
Early Bird Deadline: January 07, 2011
Poster Abstract Deadline: December 10, 2010
During the past decade there has been a marked decline in the number of novel drugs developed and approved for treatment of schizophrenia despite a significant investment in research and development by the pharmaceutical industry. The goal of this conference is to facilitate the translation of discoveries in basic neuroscience into the development of innovative pharmacological agents for the treatment of schizophrenia by convening and encouraging dialogue among clinical, translational and basic neuroscientists. Plenary sessions will include discussion of genetic and epigenetic approaches to studying schizophrenia; new molecular targets and approaches to small molecule therapeutics; and the relationship between genes, function, and clinical symptoms.
Submitted by Anna